Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants

The emergence of novel potentially pandemic pathogens necessitates the rapid manufacture and deployment of effective, stable, and locally manufacturable vaccines on a global scale. In this study, the ability of the Escherichia coli expression system to produce the receptor binding domain (RBD) of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasubramaniyam, Arasu, Ryan, Emma, Brown, Dallas, Hamza, Therwa, Harrison, William, Gan, Michael, Sankhala, Rajeshwer S., Chen, Wei-Hung, Martinez, Elizabeth J., Jensen, Jaime L., Dussupt, Vincent, Mendez-Rivera, Letzibeth, Mayer, Sandra, King, Jocelyn, Michael, Nelson L., Regules, Jason, Krebs, Shelly, Rao, Mangala, Matyas, Gary R., Joyce, M. Gordon, Batchelor, Adrian H., Gromowski, Gregory D., Dutta, Sheetij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864931/
https://www.ncbi.nlm.nih.gov/pubmed/36679887
http://dx.doi.org/10.3390/vaccines11010042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864931/
https://www.ncbi.nlm.nih.gov/pubmed/36679887
http://dx.doi.org/10.3390/vaccines11010042

Ejemplares similares